EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2026 Interim Results at a glance

2026.08.05

H1 2026 Results Announcement: Regulatory Headwinds Drag Down, Revenue by 10.5% to HK$784.7 million and Profit by 32.2% to HK$110.7 million, Interim Dividend HK$0.05

2026.08.05

Essex Bio-Technology enters Strategic Collaboration Framework Agreement with Gunze Medical to further Commercial Access and to advance Research in Regenerative Medicine and Wound Care

2026.07.23

Date

Title

2020-08-10

Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech

2020-04-30

Essex Bio-Technology Joins X-ZELL Seed+ Investment Round

2020-03-17

FY 2019 Profit-After-Tax Up 30.9% to HK$302.5 million,was up 36.5% in RMB denomination

2019-12-27

Preservative-free Single-dose rb-bFGF Eye Drops (Single-Dose Beifushu Eye Drops) Obtained Approval from NMPA for Commercialisation in China

2019-12-12

Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1

2019-08-21

Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List

2019-08-12

Essex Biotech's mid-2019 net profit increased by 31% year-on-year to HK$129 million

2019-08-02

Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT